Skip to main content
Journal cover image

Furosemide Exposure and Prevention of Bronchopulmonary Dysplasia in Premature Infants.

Publication ,  Journal Article
Greenberg, RG; Gayam, S; Savage, D; Tong, A; Gorham, D; Sholomon, A; Clark, RH; Benjamin, DK; Laughon, M; Smith, PB ...
Published in: J Pediatr
May 2019

OBJECTIVE: To evaluate the association between furosemide exposure and risk of bronchopulmonary dysplasia (BPD). STUDY DESIGN: This retrospective cohort study included infants (2004-2015) born at 23-29 weeks gestational age and 501-1249 g birth weight. We compared the demographic and clinical characteristics of infants exposed and not exposed to furosemide between postnatal day 7 and 36 weeks postmenstrual age. We examined the association between furosemide exposure and 2 outcomes: BPD and BPD or death. We performed multivariable probit regression models that included demographic and clinical variables in addition to 2 instrumental variables: furosemide exposure by discharge year, and furosemide exposure by site. RESULTS: Of 37 693 included infants, 19 235 (51%) were exposed to furosemide; these infants were more premature and had higher respiratory support. Of 33 760 infants who survived to BPD evaluation, 15 954 (47%) had BPD. An increase in the proportion of furosemide exposure days by 10 percentage points was associated with a decrease in both the incidence of BPD (4.6 percentage points; P = .001), and BPD or death (3.7 percentage points; P = .01). CONCLUSIONS: More days of furosemide exposure between postnatal day 7 and 36 weeks was associated with decreased risk of BPD and a combined outcome of BPD or death.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Pediatr

DOI

EISSN

1097-6833

Publication Date

May 2019

Volume

208

Start / End Page

134 / 140.e2

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Sodium Potassium Chloride Symporter Inhibitors
  • Retrospective Studies
  • Pediatrics
  • Multivariate Analysis
  • Male
  • Infant, Very Low Birth Weight
  • Infant, Premature, Diseases
  • Infant, Premature
  • Infant, Newborn
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Greenberg, R. G., Gayam, S., Savage, D., Tong, A., Gorham, D., Sholomon, A., … Best Pharmaceuticals for Children Act—Pediatric Trials Network Steering Committee, . (2019). Furosemide Exposure and Prevention of Bronchopulmonary Dysplasia in Premature Infants. J Pediatr, 208, 134-140.e2. https://doi.org/10.1016/j.jpeds.2018.11.043
Greenberg, Rachel G., Sreepriya Gayam, Destiny Savage, Andrew Tong, Daniel Gorham, Ari Sholomon, Reese H. Clark, et al. “Furosemide Exposure and Prevention of Bronchopulmonary Dysplasia in Premature Infants.J Pediatr 208 (May 2019): 134-140.e2. https://doi.org/10.1016/j.jpeds.2018.11.043.
Greenberg RG, Gayam S, Savage D, Tong A, Gorham D, Sholomon A, et al. Furosemide Exposure and Prevention of Bronchopulmonary Dysplasia in Premature Infants. J Pediatr. 2019 May;208:134-140.e2.
Greenberg, Rachel G., et al. “Furosemide Exposure and Prevention of Bronchopulmonary Dysplasia in Premature Infants.J Pediatr, vol. 208, May 2019, pp. 134-140.e2. Pubmed, doi:10.1016/j.jpeds.2018.11.043.
Greenberg RG, Gayam S, Savage D, Tong A, Gorham D, Sholomon A, Clark RH, Benjamin DK, Laughon M, Smith PB, Best Pharmaceuticals for Children Act—Pediatric Trials Network Steering Committee. Furosemide Exposure and Prevention of Bronchopulmonary Dysplasia in Premature Infants. J Pediatr. 2019 May;208:134-140.e2.
Journal cover image

Published In

J Pediatr

DOI

EISSN

1097-6833

Publication Date

May 2019

Volume

208

Start / End Page

134 / 140.e2

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Sodium Potassium Chloride Symporter Inhibitors
  • Retrospective Studies
  • Pediatrics
  • Multivariate Analysis
  • Male
  • Infant, Very Low Birth Weight
  • Infant, Premature, Diseases
  • Infant, Premature
  • Infant, Newborn